Beyond the psychedelic hype: Exploring the persistence of the neoliberal paradigm

Psychedelic medicine is promoted as a novel solution to the mental health crisis, but the psychedelics industry adopts profit-driven approaches similar to those that undermined earlier antidepressants like SSRIs. The liberatory rhetoric of psychedelic medicalization actually promotes individualized treatments for distress, distracting from systemic changes needed to address root causes like inequality, precarity, exploitation, and ecological collapse. Through mechanisms of depoliticization, productivization, pathologization, commodification, and de-collectivization, the industry aligns with neoliberal ideology rather than disrupting the psychopharmaceutical status quo. The authors conclude that psychedelics must decouple from neoliberal incentives to achieve durable improvements in well-being.

Study at a glance

Abstract

Abstract Background and Aims Advocates of psychedelic medicine have positioned psychedelics as a novel therapeutic intervention that will solve the mental health crisis by liberating individuals from their entrenched habits and limiting beliefs. Despite claims for novelty, the psychedelics industry is engaging in the same profit-oriented approaches that contributed to poor clinical outcomes with SSRIs and other earlier pharmaceuticals, which threatens to undermine their purported clinical benefits. Methods We present evidence that the liberatory rhetoric of psychedelic medicalization promotes neoliberal, individualised treatments for distress, which distracts from collective efforts to address root causes of suffering through systemic change. Drawing examples from the psychedelics industry, we illustrate how the discourse of psychedelic medicalisation subjects socially-determined distress to psychotropic intervention through the mechanisms of depoliticisation, productivisation, pathologisation, commodification, and de-collectivisation. Results Rather than disrupting or subverting the psychopharmaceutical status quo, the psychedelic industry's current instantiation aligns with and upholds key facets of neoliberal ideology by adhering to the same facilitative mechanisms that scholars identified in the antidepressant industry. We identify these common mechanisms in examples unique to the psychedelics industry, including the search for psychedelic analogues and political lobbying to reschedule psychedelics. Conclusion We demonstrate how a neoliberal mental health paradigm that individualises and interiorizes mental distress cannot meaningfully resolve suffering with ubiquitous origins in the current sociopolitical environment, which is characterised by inequality, precarity, exploitation, and ecological collapse. As a result, psychedelics must decouple from neoliberal incentives, and demonstrate efficacy, if they are to facilitate durable improvements in well-being and prosocial outcomes.